ArticleBMJ (Clinical research ed.)2012
Cost effectiveness of human papillomavirus test of cure after treatment for cervical intraepithelial neoplasia in England: economic analysis from NHS Sentinel Sites Study.
Article in BMJ (Clinical research ed.), 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 3 syntheses or guidelines pooled it, 37 citations in OpenAlex.
- Human Papillomavirus Genotyping Compared With a Qualitative High-Risk Human Papillomavirus Test After Treatment of High-Grade Cervical Intraepithelial Neoplasia: A Systematic Review.Obstetrics and gynecology · 2019Pooled it
- Systematic review of model-based cervical screening evaluations.BMC cancer · 2015Pooled it
- The incidence of human papillomavirus infection following treatment for cervical neoplasia: a systematic review.Gynecologic oncology · 2014Pooled it
- Benefits, harms and cost-effectiveness of cervical screening, triage and treatment strategies for women in the general population.Nature medicine · 2023Article
- Projected time to elimination of cervical cancer in the USA: a comparative modelling study.The Lancet. Public health · 2020Article
- Diagnostic excision of the cervix in women over 40 years with human papilloma virus persistency and normal cytology.European journal of obstetrics & gynecology and reproductive biology: X · 2019Article
- Article
- Projected future impact of HPV vaccination and primary HPV screening on cervical cancer rates from 2017-2035: Example from Australia.PloS one · 2018Article
- Article
- Transitioning from cytology-based screening to HPV-based screening at longer intervals: implications for resource use.BMC health services research · 2016Article
- Effectiveness Modelling and Economic Evaluation of Primary HPV Screening for Cervical Cancer Prevention in New Zealand.PloS one · 2016Article
- HPV-Testing in Follow-up of Patients Treated for CIN2+ Lesions.Journal of Cancer · 2016Review
- Long-term costs of introducing HPV-DNA post-treatment surveillance to national cervical cancer screening in Ireland.Expert review of pharmacoeconomics & outcomes research · 2015Article
- Effect of ageing on cervical or vaginal cancer in Swedish women previously treated for cervical intraepithelial neoplasia grade 3: population based cohort study of long term incidence and mortality.BMJ (Clinical research ed.) · 2014Article
- Expenditure and resource utilisation for cervical screening in Australia.BMC health services research · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo evaluate the cost effectiveness of human papillomavirus testing after treatment for cervical intraepithelial neoplasia (CIN).
designEconomic analysis using a Markov modelling approach to combine cost and epidemiological data from the NHS Sentinel Sites Study with data from previous studies of post-treatment recurrence rates.
settingEnglish NHS Cervical Cancer Screening Programme.
interventionsManagement guidelines after treatment of CIN involving annual cytology follow-up for 10 years, compared with alternative protocols using the human papillomavirus test to reduce the amount of post-treatment surveillance.
main outcome measuresCases of underlying CIN3+ averted at 10 years and costs per 1000 women treated.
resultsModel predictions indicated that, at observed levels of compliance with post-treatment recommendations, management with only cytological follow-up would result in 29 residual cases of recurrent CIN3+ by 10 years and would cost £358,222 (€440,426; $574,910) (discounted) per 1000 women treated. Implementation of human papillomavirus test of cure in cytologically negative women according to the sentinel sites protocol would avert an additional 8.4 cases of CIN 3+ and reduce costs by £9388 per 1000 women treated.
conclusionsHuman papillomavirus test of cure would be more effective and would be cost saving compared with cytology only follow-up. The results of this evaluation support the full scale implementation of human papillomavirus test of cure after treatment of CIN within the NHS Cervical Screening Programme.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.